STOCK TITAN

Tiziana Life Sciences Ltd. (TLSA) Stock News, Jan-Apr 2024

TLSA NASDAQ

Tiziana Life Sciences Ltd. develops intranasal foralumab, a fully human anti-CD3 monoclonal antibody, as a clinical-stage biotechnology company focused on neuroinflammatory and neurodegenerative diseases. News for TLSA centers on clinical and preclinical data for intranasal anti-CD3 therapy, including non-active secondary progressive multiple sclerosis, Multiple System Atrophy, Alzheimer’s disease, ALS, Long COVID-associated neuroinflammation, and age-related cognitive decline.

Company updates also cover biomarker work involving CSF proteomics, TSPO-PET and microglial activation, peer-reviewed publications, scientific conference presentations, expanded-access observations, and financing actions such as registered direct offerings of ordinary shares and warrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.15%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.06%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.60%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.79%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none

FAQ

What is the current stock price of Tiziana Life Sciences (TLSA)?

Tiziana Life Sciences (TLSA) last closed at $0.6480.

What is the market cap of Tiziana Life Sciences (TLSA)?

The market cap of Tiziana Life Sciences (TLSA) is approximately $83.0M.